To explore the influence of Qingqihuatan Decoction combined with chemotherapy on CEA, CA125 and CYFRA21-1 in treating patients with non-small cell lung cancer at middle-late stage of phlegm heat resistance pulmonary syndrome.Methods:40 patients with non-small cell lung cancer at middle-late stage of phlegm heat resistance pulmonary syndrome who were treated in our hospital from January 2013 to December 2016 were randomly divided into a control group of 20 cases and an observation group of 20 cases.The patients in the control group were given pemetrexed and cisplatin for chemotherapy; while the patients in the observation group were given Qingqihuatan Decoction on the basis of control treatment.The paper was aimed at observing the recent curative effect，evaluating the living quality, monitoring the levels of CEA, CA125 and CYFRA21-1, and recording the adverse reactions.Results:The recent efficiency of the patients in observation group was 65.0%, which was higher than 30%of the control group (P<0.05); the living quality scores of emotional, activity function, physical and social for the patients in observation group were higher than that of the control group (P<0.05); the levels of CEA, CA125 and CYFRA21-1 of the patients in observation group was lower than that of the control group (P<0.05); Two groups of patients had adverse reactions such as nausea, vomiting, constipation, reduced platelet and white blood cells, hair loss, and liver and kidney impairment, the incidence of observation group were significantly lower (P<0.05).Conclusion:The therapy can improve the patients' living quality.It has the advantage of toxicity reducing and efficacy enhancing.The mechanism may be associated with regulating CEA, CA125 and CYFRA21-1 to induce apoptosis of cancer cells, and it is worthy of clinical promotion.